Lumpectomy Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 – 2034

Lumpectomy Market Size

The global lumpectomy market generated considerable revenues in 2024 and is projected to grow at a decent CAGR between 2025 and 2034, due to rising breast cancer incidences and a preference for breast-conserving surgeries. As per American Cancer Society there were about 310,720 new cases of invasive breast cancer and 56,500 cases of ductal carcinoma in situ (DCIS) diagnosed among U.S. women in 2024 and 42,250 women died from breast cancer.
 

Market growth has been significantly contributed by increased emphasis on early detection of breast cancers, improved imaging technologies, and enhanced surgical outcomes. Lumpectomy, or breast-conserving surgery or wide local excision, enables the removal of malignant tissue while conserving breast tissue, resulting in both physical and psychological benefits over mastectomy.
 

The increasing global burden of breast cancer, which is still one of the most frequently diagnosed cancers in women, has contributed to the growth of lumpectomy procedures. Increased screening initiatives and advancements in diagnosis accuracy led to increased diagnoses of early-stage cancers allowing for more patients to undergo breast-conserving lumpectomy surgery versus an invasive procedure. Overall, surgical improvements, such as precision-guided lumpectomy devices and margin evaluation systems, have improved procedural success rates and decreased re-excision requirements. Despite this positive growth towards breast-conserving lumpectomy, the market still faces certain limitations, including procedure costs.
 

Lumpectomy Market Trends

Various trends are impacting the future of the lumpectomy market. One key trend is a shift toward minimally invasive and image-guided procedures. Newer technologies such as intraoperative imaging, optical coherence tomography, and margin mapping have changed the way lumpectomies are performed, allowing for tumors to be removed with precision while maintaining a healthy margin and sandwiching in-situ cancers. Another trend, which is somewhat more proactive, is the application of AI and machine learning algorithms to assist with preoperative planning, real-time surgical decision-making, and postoperative monitoring. These advances are resulting in fewer re-excisions, better surgical margins, and ultimately better long-term patient outcomes.
 

Wireless localization systems are also being embraced, giving patients an appealing option instead of conventional wire-guided localization. These systems not only help improve the efficiency or workflow of surgery but also allow for scheduling flexibility in the busy world of hospitals and outpatient procedures. New developments in the concept of personalized oncology are also coming into play, as tumor profiling and genomic tests help to determine the extent of surgery and any adjuvant therapy considerations. The push towards patient-centered care (with an emphasis on quality of life) and improved cosmetic outcomes is shaping decisions made by the surgical oncology team, favoring lumpectomy over other more radical approaches.
 

Lastly, the healthcare world is now more complex than ever, with various stakeholders approaching decisions from different perspectives (cost vs efficiency vs satisfaction). The information presented suggests that the lumpectomy market is changing, simply because of the new tools and the educational benefits of new technologies.
 

Lumpectomy Market Analysis

The lumpectomy systems segment held the largest share in 2024 driven by the surgical tools or devices used to excise tumors and assess margins intraoperatively. Products in this segment include Radiofrequency Guided Localization Systems, scalpel-based excision instruments, electrosurgical devices, and tissue marking systems. This segment captured the largest revenue in 2023, because of its importance in improving quality, avoiding cancer recurrence, and accuracy. Companies have begun to create innovative lumpectomy systems, with the latest capabilities being advanced imaging-guided systems to provide the surgeon with real-time tumor margin visualization.
 

Minimally invasive lumpectomy systems are commonly utilized when patients undergo outpatient, as well as when patients belong to a hospital. There are several systems promoting wireless localization, in place of wire-guided localization, which can cause discomfort, logistical delays, or scheduling issues with the wire-guided localization. Collectively, these new systems are creating better logical processes, increasing the efficiency of procedures, improving accuracy, and aligning with more productive surgical environments for workflow processes.
 

The lumpectomy market from ambulatory surgical centers (ASC) segment generated notable revenues in 2024. The healthcare industry is embracing outpatient procedures that are cost-effective, efficient, and minimally aimed toward invasive treatment. There are benefits of ASCs specifically for outpatient lumpectomy procedures because they are typically short, they have a lower rate of complications, and they have a lower rate of post-operative recovery time. Patients appreciate ASCs considering their convenience, shorter hospitalizations, and the less overall expense compared to procedures conducted in traditional hospitals.
 

Alongside traditional outpatient models, increased development of anesthesia techniques, pain management techniques, and same-day discharge where lumpectomy can be incorporated into an ambulatory procedure have empowered ASCs to develop and utilize operational efficiencies. For the ASC, renewed interest and increased utilization of ASCs position them favorably with streamlined operations, accelerated procedure, scheduling, and overhead fees to provide a lower cost and expand services to a wider range of patients. There will be continued demand for lumpectomy services offered in ASCs with the increasing incidence of early-stage breast cancer and early detection. The market demand will trend upwards, particularly in urban areas with advantageous healthcare access.
 

North America lumpectomy market will continue to hold robust position during 2025-2034 driven by the high breast cancer incidence rate, high levels of adoption of surgical technologies, and a strong healthcare infrastructure. The US is the largest contributor, followed by some distance by Canada. The US also leads in new awareness campaigns, government-assisted screening, access to innovative treatment paradigms, and robust public funding for breast cancer in leading-edge treatment. There is a higher growing demand for breast-conserving surgery than mastectomy, given patient preference for better cosmetic outcomes.
 

The presence of major medical device companies that focus on designing and commercializing lumpectomy systems also contributes to regional growth. In addition, reimbursement policy has significantly contributed to an increase in health insurance payment levels, improved accessibility to alternative procedures (with skilled surgical professionals), and recent model outpatient surgery and value-based care models now allow ambulatory surgical centers to be advanced, thereby removing limits to access.
 

Lumpectomy Market Share

Key players in the lumpectomy industry include:

• ClearCut Medical
• Hologic Inc.
• Endomagnetics Ltd.
• Cianna Medical
• Carl Zeiss Meditec AG
• Novian Health Inc.
• Focal Therapeutics Inc.
• Ranfac Corporation
• Dune Medical Devices
• Vector Surgical LLC
• Theragenics
• iCAD Inc.
   

To solidify their existing market position, the leading companies operating in the lumpectomy market are focusing on product innovation, strategic partnerships, and geographic growth. They are focusing on developing advanced imaging-guided surgical systems, wireless localization, and AI-augmented margin assessment technologies to promote surgical precision and enhance patient outcomes. Allied partnerships with hospitals and ambulatory surgical centers are helping to expand their reach and promote the acceptance of new devices. In emerging markets, companies continue to create more affordable solutions and invest in local manufacturing. In addition, many companies pursue direct acquisitions or mergers to bring complementary technologies and broaden their product portfolio and scope.
 

Lumpectomy Industry News

• In January 2025, Lumicell, Inc. announced that LumiSystem™ was commercially available and had been used for the first time in the U.S. The system combined two FDA-approved tools—LUMISIGHT™, a fluorescent imaging agent, and the Lumicell™ Direct Visualization System, which helped surgeons detect cancerous tissue inside the breast during lumpectomy.
   
• In May 2025, Florida Cancer Specialists & Research Institute offered shorter radiation treatment for women with early-stage breast cancer at their Ocala and Villages Cancer Centers. Accelerated Partial Breast Irradiation (APBI) uses powerful X-rays to target cancer quickly and provides several benefits for patients.